Insights
Analysis that starts from specific chemicals and raw materials — grounded in published literature, company announcements, regulatory documents, and industry data — unpacking the science, manufacturing, and compliance behind them, alongside chemical regulations, materials technology, company moves, and supply-chain risks. Fact-based industry observation and judgment.
Continue through the broader archive covering procurement, compliance, supplier evaluation, and product workflow topics.
Page 2
A synthesis route becomes public the moment its patent expires — but most of what actually decides whether a molecule can be made reliably, safely, and cheaply never gets written down. Four layers trace the gap between a public route and a defensible manufacturing capability: process development, scale-up, accumulated tacit experience, and where AI does and doesn't fit.
The modern materials revolution isn't a search for the best material — it's a search for one with no weak dimension. From molecular design to aerospace, AI, and clean energy, this piece traces why metal is losing ground, and why only a handful of companies can actually manufacture the polymers taking its place.
The hardest part of making OLED was never getting a molecule to glow — it's controlling electrons: where electrons and holes go, where excitons form, and how to keep that from running wild over tens of thousands of hours. This piece walks through seven barriers to answer why so few companies can pull it off.
Cyantraniliprole, pinoxaden, and sulfoxaflor all lose patent protection between 2026 and 2027. The common assumption is that any manufacturer with capacity can now copy the molecule. What usually decides whether that actually happens is whether the key intermediates are available at all.
An AI chip isn't just bigger than an ordinary chip — it passes through more lithography, etch, clean, and polish cycles, each consuming ultra-high-purity photoresist, CMP slurry, electronic-grade HF, sulfuric acid, and PGMEA at parts-per-trillion purity. A fact-based map of why this supply chain is short, hard to switch suppliers on, and now visibly tightening.
Suzuki-Miyaura coupling has quietly become the default platform reaction in small-molecule API manufacturing, shaping which building blocks get sourced and whether a route can scale to metric tons. A fact-based look at why one reaction, from Losartan to Sotorasib, still anchors modern pharmaceutical supply chains four decades after its discovery.
A single pyridine intermediate feeds four different neonicotinoid insecticides. A single pyrazole acid feeds a whole family of SDHI fungicides. This isn't coincidence — it's the Reaction Interface Economy, the organizing logic behind modern agrochemical R&D and its supply chain.
Fluorine is not an ordinary element but a tuning knob for molecular performance - one element that underpins drugs, agrochemicals, semiconductors, and batteries at once. This deep dive traces the C-F bond's performance leverage, why fluorine dominates modern drug design, why NF3/CF4/SF6 are irreplaceable in chip etching, the fluorite-to-HF value chain that four industries share, and why regulating PFAS (a structural, not toxicological, definition) is not the same as opposing fluorine chemistry. Every key fact cited to a primary source. Not compliance advice.
GLP-1 began as one incretin hormone in a physiology textbook; today nearly every major pharma runs a GLP-1 program. Reading the industry through the chemistry of semaglutide: why native GLP-1 (~2-minute half-life) is undruggable, how an Aib substitution + a C18 albumin-binding fatty chain turned it into a once-weekly drug, why ~31 amino acids sits near the edge of SPPS, and why the real moat is process + qualification + supply chain, not the formula. Every key number cited to a primary source. Not medical advice.
CRO, CMO and CDMO differ by a letter or two but sit at completely different points on the drug value chain, carry different regulatory responsibility, and run on different business models. A fact-based map of the boundaries, the overlap, and the CRDMO trend now stitching them back together.
Photoresist is a translator: it converts optical information into chemical information, then a physical pattern, then an electronic device. Every reduction in exposure wavelength - g-line to i-line to KrF to ArF to EUV - has forced this translator to rewrite itself, from the invention of chemical amplification at IBM in 1982 to today's photon-shot-noise limits at EUV. This deep dive traces the chemistry, the 2019 Japan-Korea export control episode, and why the real moat is process, qualification, data and time - not the formula.
Potassium ferrate is marketed as a single chemical that does what chlorine and PAC do in two steps - oxidize, then coagulate. This article explains the redox mechanism behind that dual function, why stable solid ferrate is expensive to manufacture, how its regulatory status for drinking water is evaluated product-by-product (including China's GB/T 17218 permit regime), and why it hasn't replaced chlorine and PAC at most plants. Peer-reviewed sources throughout.